- Home
- PTLO vs FDMT Comparison
PTLO vs FDMT Comparison
Compare PTLO & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTLO | FDMT |
|---|---|---|
| Founded | 1963 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.0M | 513.6M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PTLO | FDMT |
|---|---|---|
| Price | $5.18 | $8.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $8.06 | ★ $34.13 |
| AVG Volume (30 Days) | ★ 1.4M | 721.4K |
| Earning Date | 01-01-0001 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $732,066,000.00 | $37,000.00 |
| Revenue This Year | $9.71 | $21,227.03 |
| Revenue Next Year | $6.20 | $161.87 |
| P/E Ratio | $19.46 | ★ N/A |
| Revenue Growth | ★ 3.03 | N/A |
| 52 Week Low | $4.41 | $2.24 |
| 52 Week High | $14.47 | $12.34 |
Technical Indicators
Market Signals| Indicator | PTLO | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 40.86 | 41.42 |
| Support Level | $4.51 | $8.11 |
| Resistance Level | $5.30 | $8.80 |
| Average True Range (ATR) | 0.32 | 0.56 |
| MACD | -0.07 | -0.08 |
| Stochastic Oscillator | 14.49 | 3.88 |
Price Performance
Historical ComparisonAbout PTLO Portillo's Inc.
Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. It owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, Barnelli's pasta, sides and soup, and desserts and shakes.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.